GlassScriptPhysician profile
Rajeev Samtani
NPI 1659767432
$58,228.06
in general payments reported to CMS, 2019-2025
24 companies · $157 in 2025
The $157 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $69.67 · 2021: $23.50 · 2022: $28K · 2023: $14K · 2024: $16K · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $17K · Food and Beverage: $10K · Travel and Lodging: $3,121 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $17,000.00 |
| Food and Beverage | $10,410.39 |
| Travel and Lodging | $3,121.20 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $28,651.11 | 2021-2025 | Mitraclip, Pressurewire, Navitor |
| Medtronic, INC. | $20,046.66 | 2022-2024 | Corevalve Evolut R, Symplicity G3 |
| Shockwave Medical, INC | $2,841.84 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Terumo Medical Corporation | $1,473.77 | 2022-2024 | Metacross Otw, Glidesheath Slender, Angio-Seal |
| Cardiva Medical, INC. | $828.68 | 2022-2025 | Cardiva Vascade 5f Vcs, Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs |
| Edwards Lifesciences Corporation | $827.50 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Pascal |
| Boston Scientific Corporation | $701.72 | 2022-2024 | Avvigo Guidance System, Mdu5 Plus Sterile Bag, Filterwire Ez |
| Philips North America LLC | $424.20 | 2022-2024 | (Bs3) Intracardiac Und |
| Abiomed | $422.37 | 2024 | Impella |
| Amgen INC. | $356.41 | 2022-2024 | Repatha |
| Chiesi USA, INC. | $276.41 | 2023-2024 | Kengreal, Cleviprex |
| Astrazeneca Pharmaceuticals LP | $259.12 | 2020-2024 | Farxiga, Andexxa |
| Bard Peripheral Vascular, INC. | $244.35 | 2022-2024 | Ultraverse 014, Halo One Thin-Walled Guiding Sheath, Lifestent Solo Vascular Stent |
| Pfizer INC. | $226.44 | 2022-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $111.42 | 2024 | Lifevest |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $94.41 | 2024-2025 | |
| Cordis US Corp. | $93.27 | 2024 | Outback, Zephyr, Infiniti |
| E.R. Squibb & Sons, L.L.C. | $90.04 | 2020-2023 | Camzyos |
| W. L. Gore & Associates, INC. | $72.64 | 2024 | Gore Viabahn Vbx Balloon Expandable Endo |
| Kestra Medical Technology Services, INC. | $48.24 | 2024 | Assure Wcd |
| Cardiovascular Systems INC. | $46.53 | 2022 | |
| Cook Medical LLC | $34.18 | 2024 | Torcon Nb |
| Lantheus Medical Imaging, INC. | $31.14 | 2020 | |
| Asahi Intecc USA, INC. | $25.61 | 2024 | Peripheral Vascular |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajeev Samtani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.